Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.12 -0.18 (-0.74%)
Streaming Delayed Price Updated: 1:31 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market. 
Via Investor's Business Daily
Exploring the top movers within the S&P500 index during today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings
 
Via Benzinga
Pfizer's Covid Windfall Shrinks, Expands Cost-Cutting Efforts
Pfizer beats Q1 EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining. 
Via Benzinga
Earnings Scheduled For April 29, 2025
 
Via Benzinga
Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?
Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and... 
Via Benzinga
Topics Bonds
Pfizer Reports Q1 2025: Revenue Down 8% Y/Y
Pfizer's Q1 2025 results indicate a sound earnings performance, with adjusted EPS surpassing expectations. 
Via Talk Markets
Pfizer Inches Down On Mixed Report As Cost Cuts Boost Earnings
The company also reported light sales, thanks to declining sales of key products like Eliquis and Ibrance. 
Via Investor's Business Daily
Topics Government
Pfizer (NYSE:PFE) Misses Q1 Revenue Estimates
Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 7.8% year on year to $13.72 billion. The company’s full-year revenue guidance... 
Via StockStory
If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today
Things were going great, right until the point when they weren't. 
Via The Motley Fool
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
From Pfizer Inc.
Via Business Wire
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this... 
Via Benzinga
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting... 
Via Benzinga
Topics Government
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
 
Via Benzinga
US Stock Futures Climb As Traders Eye Consumer Confidence, Jobs Data: Strategist Lists 4 Factors For Sustained S&P 500 Breakout
On Monday, the major averages settled on a mixed note as traders adopted a "wait-and-watch" approach following four straight sessions of gains. 
Via Stocktwits
Topics ETFs Economy Stocks
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
What's going on in today's session: S&P500 most active stocks
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Down 36%, Is Moderna a Buy on the Dip?
Via The Motley Fool
Pfizer Stock Climbs Pre-Market On Bladder Cancer Trial Success: Retail Digests Data Ahead Of Q1 Print
Pfizer highlighted positive late-stage results for its experimental bladder cancer drug, sasanlimab, as it looks to strengthen its oncology portfolio and offset losses from recent setbacks in its... 
Via Stocktwits
Topics Intellectual Property
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Via The Motley Fool
Topics Artificial Intelligence Energy
Pfizer (PFE) Reports Q1: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Government World Trade
The Week Ahead: PCE Inflation Data And Big Tech Earnings In Focus
Markets brace for crucial week with Big Tech earnings, Trump's 100-day milestone, and key economic data as trade concerns linger. 
Via Talk Markets
Topics Economy Government Stocks / Equities
1 Superstar Dividend Growth Stock to Buy if the Market Crashes
Investors have been waiting nearly a decade to score a good deal on this healthcare star. 
Via The Motley Fool
Topics Economy Government
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout
After the closing bell, Merck said the two parties were discussing a deal at around $47 per share. 
Via Stocktwits
Most active S&P500 stocks in Thursday's session
Stay informed about the most active stocks in the S&P500 index on Thursday's session. Discover the stocks that are generating the highest trading volume and driving market activity. 
Via Chartmill
Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform
Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback